ATE246244T1 - Rekombinante cmv-neutralisierungsproteine - Google Patents

Rekombinante cmv-neutralisierungsproteine

Info

Publication number
ATE246244T1
ATE246244T1 AT93203533T AT93203533T ATE246244T1 AT E246244 T1 ATE246244 T1 AT E246244T1 AT 93203533 T AT93203533 T AT 93203533T AT 93203533 T AT93203533 T AT 93203533T AT E246244 T1 ATE246244 T1 AT E246244T1
Authority
AT
Austria
Prior art keywords
polypeptides
proteins
recombinant cmv
glycoprotein
epitope
Prior art date
Application number
AT93203533T
Other languages
English (en)
Inventor
Carol A Pachl
Richard R Spaete
Original Assignee
Aventis Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur filed Critical Aventis Pasteur
Application granted granted Critical
Publication of ATE246244T1 publication Critical patent/ATE246244T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT93203533T 1988-01-29 1989-01-26 Rekombinante cmv-neutralisierungsproteine ATE246244T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14971588A 1988-01-29 1988-01-29

Publications (1)

Publication Number Publication Date
ATE246244T1 true ATE246244T1 (de) 2003-08-15

Family

ID=22531490

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93203533T ATE246244T1 (de) 1988-01-29 1989-01-26 Rekombinante cmv-neutralisierungsproteine

Country Status (10)

Country Link
US (2) US6190860B1 (de)
EP (2) EP0609580B1 (de)
JP (2) JP2607712B2 (de)
AT (1) ATE246244T1 (de)
AU (1) AU641121B2 (de)
CA (1) CA1340832C (de)
DE (1) DE68929478T2 (de)
DK (1) DK176055B1 (de)
FI (1) FI109604B (de)
WO (1) WO1989007143A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100064A (en) * 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
US6162620A (en) * 1986-03-07 2000-12-19 Cogent Limited Processes for the production of HCMV glycoproteins, antibodies thereto and HCMV vaccines, and recombinant vectors therefor
US5124440A (en) * 1986-11-24 1992-06-23 The Childrens Hospital, Inc. Antibody and T cell recognition sites on glycoproteins comprising the GCI complex of human cytomegalovirus
US5552143A (en) * 1989-03-24 1996-09-03 The Wistar Institute Of Anatomy & Biology Recombinant cytomegalovirus vaccine
US5591439A (en) * 1989-03-24 1997-01-07 The Wistar Institute Of Anatomy And Biology Recombinant cytomegalovirus vaccine
GB9008223D0 (en) * 1990-04-11 1990-06-13 Royal Free Hosp School Med Improvements relating to the detection of viruses
US5997878A (en) * 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
JPH07502655A (ja) * 1991-12-23 1995-03-23 バイエル　コーポレイション 溶液相サンドイッチハイブリダイゼーションアッセイに用いるためのｃｍｖプローブ
GB9409962D0 (en) * 1994-05-18 1994-07-06 Smithkline Beecham Biolog Novel compounds
WO1997012042A2 (en) * 1995-09-26 1997-04-03 University Of Washington Glycoprotein b of the rfhv/kshv subfamily of herpes viruses
WO1997040165A1 (en) * 1996-04-23 1997-10-30 The Wistar Institute Of Anatomy And Biology Novel human cytomegalovirus dna constructs and uses therefor
AU2172800A (en) * 1998-12-10 2000-06-26 Washington University Protein transduction system and methods of use thereof
CA2363141C (en) 1999-02-26 2010-04-06 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
AU2002355197A1 (en) 2001-07-27 2003-02-17 Chiron Srl Meningococcus adhesins nada, app and orf 40
PT2311848E (pt) 2002-12-23 2013-10-03 Vical Inc Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
WO2011005799A2 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
US8802106B2 (en) 2009-10-30 2014-08-12 The Administrators Of The Tulane Educational Fund Peptide compositions and methods for inhibiting herpesvirus infection
NZ600974A (en) 2009-12-23 2014-08-29 4Antibody Ag Binding members for human cytomegalovirus
NZ606591A (en) 2010-07-06 2015-02-27 Novartis Ag Cationic oil-in-water emulsions
EP2502631A1 (de) * 2011-03-22 2012-09-26 Medizinische Hochschule Hannover Immunsuppressor und seine Verwendung
CN103781470A (zh) 2011-07-06 2014-05-07 诺华股份有限公司 包含核酸的水包油乳液
EP3456316A1 (de) 2011-07-06 2019-03-20 GlaxoSmithKline Biologicals S.A. Kationische öl-in-wasser-emulsionen
AU2012322704B2 (en) 2011-10-11 2017-09-07 Novartis Ag Recombinant self-replicating polycistronic RNA molecules
AU2012335277B2 (en) 2011-11-11 2018-06-14 Variation Biotechnologies Inc. Compositions and methods for treatment of cytomegalovirus
DK3077519T3 (en) * 2013-12-03 2021-06-14 Hookipa Biotech Gmbh Cmv-vacciner
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
DK3471760T3 (da) 2016-06-17 2025-01-27 Boehringer Ingelheim Vetmedica Gmbh Hidtil ukendte immunogene formuleringer, der omfatter lineære eller forgrenede polyacrylsyrepolymeradjuvanser
CA3050914A1 (en) * 2017-01-27 2018-08-02 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
JP7546485B2 (ja) 2018-10-25 2024-09-06 Ｋｍバイオロジクス株式会社 改変ＣＭＶ ｇＢタンパク質及びこれを含むＣＭＶワクチン
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
CN112662694A (zh) * 2020-12-25 2021-04-16 康九生物科技(长春)有限公司 一种麦芽糖结合蛋白、麦芽糖结合蛋白表达载体、重组工程菌及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313927A (en) * 1979-10-19 1982-02-02 Ames-Yissum Ltd. Immunoassay method for detecting viral antibodies in whole blood samples
US4554101A (en) * 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4460689A (en) * 1982-04-15 1984-07-17 Merck & Co., Inc. DNA Cloning vector TG1, derivatives, and processes of making
US4762780A (en) * 1984-04-17 1988-08-09 The Regents Of The University Of California Method and composition for screening and diagnosing "HCMV"
US5173402A (en) * 1982-11-02 1992-12-22 The Regents Of The University Of California Method and compositions for screening and diagnosing human cytomegalovirus ("hCMV")
US4783399A (en) * 1984-05-04 1988-11-08 Scripps Clinic And Research Foundation Diagnostic system for the detection of cytomegalovirus
DE3585578D1 (de) * 1984-06-18 1992-04-16 Chiron Corp Hepatitisoberflaechenantigenpartikelvakzin.
US5075213A (en) * 1984-07-27 1991-12-24 City Of Hope Method for detection and prevention of human cytomegalovirus infection
US4689225A (en) * 1984-11-02 1987-08-25 Institut Merieux Vaccine for cytomegalovirus
EP0248909B1 (de) * 1985-12-06 1994-08-17 Teijin Limited Anticytomegaloviraler menschlicher monoklonaler antikörper und dessen herstellung
CA1335429C (en) 1986-03-07 1995-05-02 Geoffrey L. Smith Processes for the production of hcmv glycoproteins, antibodies thereto and hcmv vaccines, and recombinant vectors therefor
DE3619720A1 (de) * 1986-06-12 1987-12-17 Behringwerke Ag Hauptglykoprotein des menschlichen cytomegalovirus, seine herstellung und verwendung
US5124440A (en) * 1986-11-24 1992-06-23 The Childrens Hospital, Inc. Antibody and T cell recognition sites on glycoproteins comprising the GCI complex of human cytomegalovirus
US5126130A (en) * 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
US5403711A (en) * 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
EP0413738A1 (de) * 1988-05-09 1991-02-27 The Children's Hospital, Incorporated Für hcmv-glykoprotein kodierende vektoren und expressionsprodukte
US5262297A (en) * 1990-06-18 1993-11-16 Eastman Kodak Company Specific binding analytical and separation methods using carboxy containing polymers
JPH07502655A (ja) * 1991-12-23 1995-03-23 バイエル　コーポレイション 溶液相サンドイッチハイブリダイゼーションアッセイに用いるためのｃｍｖプローブ

Also Published As

Publication number Publication date
EP0436537A1 (de) 1991-07-17
WO1989007143A1 (en) 1989-08-10
FI109604B (fi) 2002-09-13
US5834307A (en) 1998-11-10
EP0609580B1 (de) 2003-07-30
JPH09176190A (ja) 1997-07-08
DE68929478D1 (de) 2003-09-04
EP0609580A1 (de) 1994-08-10
DK179290A (da) 1990-09-28
JP2607712B2 (ja) 1997-05-07
DE68929478T2 (de) 2004-04-29
EP0436537A4 (en) 1992-04-08
CA1340832C (en) 1999-11-30
US6190860B1 (en) 2001-02-20
JPH03503478A (ja) 1991-08-08
FI903724A0 (fi) 1990-07-25
DK176055B1 (da) 2006-02-27
AU3041389A (en) 1989-08-25
DK179290D0 (da) 1990-07-27
AU641121B2 (en) 1993-09-16

Similar Documents

Publication Publication Date Title
ATE246244T1 (de) Rekombinante cmv-neutralisierungsproteine
ATE97164T1 (de) Rekombinantes vaccinia-virus mva.
ATE316099T1 (de) Immunotherapeutische methoden mit verwendung von wt-1 and gata-1 epitopen
LU88256I2 (de)
DK79190A (da) Praktisk taget rent polypeptid og dets anvendelse; rekombinantvirus, rekombinantvirus, rekomninant-dna-vektor og encellet organisme til dets fremstilling
ATE364083T1 (de) Immunogene zusammensetzungen gegen eine helicobacterinfektion, verwendung von polypeptiden in diesen zusammensetzungen und nukleinsäurendie besagte polypeptide kodieren
DK1253201T3 (da) Kyllingeanæmivirusmutanter og vacciner baseret på det virale protein VP3 eller sekvenser af dette virus kodende derfor
NO882380D0 (no) Fibfonektin-bindende protein, samt fremstilling derav.
DE3751727D1 (de) Polypeptide zur verwendung bei der diagnose von mycoplasmainfektionen bei schweinen, sowie rekombinant-dns-verfahren zur herstellung derselben
NO922421D0 (no) Collagenbindende protein, samt fremstilling derav
PT638316E (pt) Vacinas de adenoviros recombinante
ATE76099T1 (de) Dns-sequenz, vektoren, rekombinante viren und verfahren zur verwendung rekombinanter vaccinia- viren, die sich in cho-zellen vermehren koennen.
DE3853693D1 (de) DNA- und RNA-Moleküle des westlichen Subtyps des FSME-Virus, Polypeptide, die von diesen Molekülen codiert werden, und deren Verwendung.
ATE116860T1 (de) Pseudorabiesvirus-impfstoff.
EP0433378A4 (en) Allelic variants of -i(plasmodium falciparum) merozoite surface antigen
DE69012989D1 (de) Peptiden von retinblastoma gen produkten und antikoerper dagegen.
MY106940A (en) Allelic variants of plasmodium falciparum merozoite surface antigen.
NZ311874A (en) Recombinant and/or pure preparations of H. pylori polypeptides and nucleic acids which are useful for diagnostics and vaccines

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0609580

Country of ref document: EP

EELA Cancelled due to lapse of time